Literature DB >> 11567815

EGFR overexpression and radiation response in glioblastoma multiforme.

F G Barker1, M L Simmons, S M Chang, M D Prados, D A Larson, P K Sneed, W M Wara, M S Berger, P Chen, M A Israel, K D Aldape.   

Abstract

PURPOSE: Recent studies have suggested relative radioresistance in glioblastoma multiforme (GM) tumors in older patients, consistent with their shorter survival. Two common molecular genetic abnormalities in GM are age related: epidermal growth factor receptor (EGFR) overexpression in older patients and p53 mutations in younger patients. We tested whether these abnormalities correlated with clinical heterogeneity in GM response to radiation treatment. METHODS AND MATERIALS: Radiographically assessed radiation response (5-level scale) was correlated with EGFR immunoreactivity, p53 immunoreactivity, and p53 exon 5-8 mutation status in 170 GM patients treated using 2 prospective clinical protocols. Spearman rank correlation and proportional-odds ordinal regression were used for univariate and multivariate analysis.
RESULTS: Positive EGFR immunoreactivity predicted poor radiographically assessed radiation response (p = 0.046). Thirty-three percent of tumors with no EGFR immunoreactivity had good radiation responses (>50% reduction in tumor size by CT or MRI), compared to 18% of tumors with intermediate EGFR staining and 9% of tumors with strong staining. There was no significant relationship between p53 immunoreactivity or mutation status and radiation response. Significant relationships were noted between EGFR score and older age and between p53 score or mutation status and younger age.
CONCLUSION: The observed relative radioresistance of some GMs is associated with overexpression of EGFR.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11567815     DOI: 10.1016/s0360-3016(01)01609-1

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  59 in total

1.  Treatment of cultured glioma cells with the EGFR-TKI gefitinib ("Iressa", ZD1839) increases the uptake of astatinated EGF despite the absence of gefitinib-mediated growth inhibition.

Authors:  Asa Liljegren Sundberg; Ylva Almqvist; Vladimir Tolmachev; Jörgen Carlsson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-03-07       Impact factor: 9.236

2.  One-step tumor detection from dynamic morphology tracking on aptamer-grafted surfaces.

Authors:  Mohammed Arif I Mahmood; Mohammad Raziul Hasan; Umair J M Khan; Peter B Allen; Young-Tae Kim; Andrew D Ellington; Samir M Iqbal
Journal:  Technology (Singap World Sci)       Date:  2015-11-16

Review 3.  Impact of molecular profiling on clinical trial design for glioblastoma.

Authors:  Arnab Chakravarti; Erin Tyndall; Kamalakannan Palanichamy; Minesh Mehta; Kenneth Aldape; Jay Loeffler
Journal:  Curr Oncol Rep       Date:  2007-01       Impact factor: 5.075

Review 4.  Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies.

Authors:  Edwin Li; Kalina Hristova
Journal:  Biochemistry       Date:  2006-05-23       Impact factor: 3.162

Review 5.  Glioblastoma multiforme: emerging treatments and stratification markers beyond new drugs.

Authors:  C von Neubeck; A Seidlitz; H H Kitzler; B Beuthien-Baumann; M Krause
Journal:  Br J Radiol       Date:  2015-07-10       Impact factor: 3.039

6.  Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.

Authors:  Paul D Brown; Sunil Krishnan; Jann N Sarkaria; Wenting Wu; Kurt A Jaeckle; Joon H Uhm; Francois J Geoffroy; Robert Arusell; Gaspar Kitange; Robert B Jenkins; John W Kugler; Roscoe F Morton; Kendrith M Rowland; Paul Mischel; William H Yong; Bernd W Scheithauer; David Schiff; Caterina Giannini; Jan C Buckner
Journal:  J Clin Oncol       Date:  2008-10-27       Impact factor: 44.544

Review 7.  HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme.

Authors:  Jeffrey J Raizer
Journal:  J Neurooncol       Date:  2005-08       Impact factor: 4.130

8.  Quantifying the strength of heterointeractions among receptor tyrosine kinases from different subfamilies: Implications for cell signaling.

Authors:  Michael D Paul; Hana N Grubb; Kalina Hristova
Journal:  J Biol Chem       Date:  2020-05-27       Impact factor: 5.157

9.  Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.

Authors:  David M Peereboom; Dale R Shepard; Manmeet S Ahluwalia; Cathy J Brewer; Neeraj Agarwal; Glen H J Stevens; John H Suh; Steven A Toms; Michael A Vogelbaum; Robert J Weil; Paul Elson; Gene H Barnett
Journal:  J Neurooncol       Date:  2009-12-04       Impact factor: 4.130

10.  Combined effect of gefitinib ('Iressa', ZD1839) and targeted radiotherapy with 211At-EGF.

Authors:  Asa Liljegren Sundberg; Ylva Almqvist; Anna Orlova; Erik Blomquist; Holger J Jensen; Lars Gedda; Vladimir Tolmachev; Jörgen Carlsson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-08-21       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.